Condition: Carcinoma, Non-Small -Cell Lung · Sponsor: Maia Biotechnology
THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®). THIO is preferentially incorporated into telomeres sequence in telomerase-positive cells leading to rapid telomere uncapping, genomic instability, and cell death. Cemiplimab is a programmed cell death protein 1 (PD-1) inhibitor recently approved as a first-line treatment for patients with locally advanced or metastatic NSCLC with 50% or more PD-L1 expression. It is hypothesized that THIO administration prior to cemiplimab would restore tumor responses to immunotherapy in subjects who either developed resistance or relapsed after receiving first line treatment with an immune check point inhibitor.
This description comes directly from the study's public registry record.
Matthew Failor · 704-936-8435 · mfailor@maiabiotech.com
Imy Chiu · ichiu@maiabiotech.com
Always discuss trial participation with your own doctor first.
| Centrum Medyczne Pratia | Poznan, Poland | Recruiting |
| Oncolab S.R.L. | Craiova, Romania | Recruiting |
| Spitalul Clinic Municipal de Urgenta Timisoara/ Clinica de Oncologie Medicala | Timișoara, Romania | Recruiting |
| Changhua Christian Hospital (CCH) | Changhua, Taiwan | Recruiting |
| Taipei Tzu Chi Hospital | Chiayi City, Taiwan | Recruiting |
| Chang-Gung Memorial Hospital - KaoHsiung | Kaohsiung City, Taiwan | Recruiting |
| Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) | Kaohsiung City, Taiwan | Recruiting |
| Chung Shan Medical University Hospital (CSMUH) | Taichung, Taiwan | Recruiting |
| Taipei Medical University Hospital (TMUH) | Taipei, Taiwan | Recruiting |
| Tri-Service General Hospital | Taipei, Taiwan | Recruiting |
| Chang-Gung Memorial Hospital - Linko | Taoyuan City, Taiwan | Recruiting |
| Medicalpark Hastanesi | Adana, Turkey (Türkiye) | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06908304